Ipca Laboratories to merge with Krebs Biochemicals

Ipca Laboratories Ltd. announced its Board of Directors has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The merger is subject to regulatory approvals. The Appointed Date for the scheme is April 1, 2026. Ipca Laboratories had a total income of ₹7431 Crores for FY26, while Krebs Biochemicals had ₹26 Crores. The transaction is considered a related party transaction but will be conducted at arm's length. Both companies operate in pharmaceutical manufacturing and marketing. The rationale includes operational synergies, cost optimization, business consolidation, and securing supply of key APIs and intermediates. No cash consideration will be paid; instead, an equity share exchange ratio of 7 shares of Ipca for every 200 shares of Krebs will be implemented.